Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy

Vascular endothelial growth factor receptors (VEGFRs) are a family of receptor protein tyrosine kinases that play an important role in the regulation of tumor-induced angiogenesis. Currently, VEGFR inhibitors have been widely used in the treatment of various tumors. However, current VEGFR inhibitors are limited to a certain extent due to limited clinical efficacy and potential toxicity, which hinder their clinical application. Thus, the development of new strategies to improve the clinical outco

Related evidence

These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.

How to cite this record

ethics.ai (7 July 2022), “Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy,” evidence record 9241, https://ethics.ai/record/9241 (originally published by OpenAlex).

Use and limitations

This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.